Kailera Therapeutics, Inc. (KLRA)
| Market Cap | 1.68B |
| Revenue (ttm) | n/a |
| Net Income | -348.24M |
| EPS | -2.69 |
| Shares Out | 129.85M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 733,266 |
| Open | 12.29 |
| Previous Close | 12.17 |
| Day's Range | 11.97 - 13.26 |
| 52-Week Range | 9.76 - 28.23 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 42.75 (+229.61%) |
| Earnings Date | Nov 4, 2026 |
About KLRA
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for KLRA stock is "Strong Buy." The 12-month stock price target is $42.75, which is an increase of 229.61% from the latest price.
News
Kailera Therapeutics initiated with a Buy at Canaccord
As previously reported, Canaccord initiated coverage of Kailera Therapeutics (KLRA) with a Buy rating and $44 price target The company’s lead asset, ribupatide, is being developed in both a subcutaneo...
Kailera Therapeutics initiated with a Buy at Canaccord
Canaccord initiated coverage of Kailera Therapeutics (KLRA) with a Buy rating and $44 price target
Kailera Reports Third Quarter 2026 Financial Results and Provides Business Updates
Ribupatide oral global Phase 3 program expected to begin in 1H 2027 following completion of End-of-Phase 2 meeting with FDA Ribupatide injection Phase 2b trial and KaiNETIC global Phase 3 program full...
Kailera Therapeutics Quarterly report: Q3 2026
Kailera Therapeutics has published its Q3 2026 quarterly earnings report on November 4, 2026.
Kailera Therapeutics Earnings release: Q3 2026
Kailera Therapeutics released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Kailera Therapeutics to Participate in November Investor Conferences
Ron Renaud, President and Chief Executive Officer, and additional members of the management team will participate in the following investor conferences
Kailera Therapeutics announces positive results from several presentations
Kailera Therapeutics (KLRA) announced Phase 1 data for ribupatide injection, a GLP-1/GIP receptor dual agonist currently advancing through global Phase 3 clinical trials, presented at the 62nd Annual ...
Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting
- New Phase 1 data highlight flexibility of injection site for ribupatide injection - Four additional oral presentations from Hengrui Pharma add to the clinical evidence behind Kailera's pipeline WALT...
Kailera Therapeutics Transcript: Stifel 2026 Virtual Cardiometabolic Forum
A broad obesity pipeline features dual and triple agonists in both injectable and oral forms, with ribupatide leading in global phase III trials and showing strong efficacy and tolerability. Key data readouts are expected in 2027–2028, supported by a cost-efficient partnership and robust IP.
Kailera announces completion of enrollment in KaiNETIC Phase 3 program
Kailera Therapeutics (KLRA) announced the completion of enrollment in the KaiNETIC global Phase 3 clinical program. The KaiNETIC program, which encompasses three trials – KaiNETIC-1, KaiNETIC-2, and K...
Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection
- Ribupatide injection (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg/m² or higher - Topline data now expected in mid-2028 WALTHAM, ...
Kailera Therapeutics Transcript: Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
Obesity treatment remains a vast, underpenetrated market with evolving pricing and access dynamics. The company is advancing differentiated GLP-1 assets, focusing on clinical efficacy, tolerability, and seamless oral/injectable options, while building commercial capabilities and leveraging AI for efficiency. Several key data readouts and catalysts are expected by 2027.
Kailera Therapeutics to Participate in September Investor Conferences
WALTHAM, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today ...
Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates
IND for ribupatide oral active with U.S. FDA, initiation of global Phase 3 obesity trials planned for the first half of 2027 Ribupatide injection Phase 2b high-dose trial in obesity fully enrolled, da...
Kailera Therapeutics Earnings release: Q2 2026
Kailera Therapeutics released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Kailera Therapeutics Quarterly report: Q2 2026
Kailera Therapeutics has published its Q2 2026 quarterly earnings report on August 12, 2026.
Kailera Therapeutics appoints Nur Nicholson as chief technology officer
Kailera Therapeutics (KLRA) announced the appointment of Nur Nicholson as chief technology officer, effective August 31. She previously served as chief technical operations officer at Apellis (APLS). ...
Kailera Therapeutics announces positive Phase 3 data for weight loss drug
Kailera Therapeutics (KLRA) announced positive topline results from two Phase 3 clinical trials conducted by its partner, Hengrui Pharma, evaluating the oral small molecule candidate HRS-7535, also kn...
Kailera's GLP-1 drug meets main goal of late-stage trials
Kailera Therapeutics said on Tuesday its GLP-1 drug for patients with diabetes and obesity met the main goal of two-late stage trials.
Kailera appoints Kathleen Tregoning as chief corporate affairs officer
Kailera Therapeutics (KLRA) announced the appointment of Kathleen Tregoning as chief corporate affairs officer. Kathleen previously served as chief corporate affairs officer and head of commercial str...
Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer
Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Ka
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and ove...
Kailera Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
A comprehensive obesity-focused pipeline is advancing, led by ribupatide in both injectable and oral forms, with multiple pivotal trials underway and key data readouts expected through 2028. Strategic collaborations, robust financials, and differentiated clinical designs position the franchise for commercial and clinical impact.
Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
WALTHAM, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced th...
Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates
Important progress across four clinical-stage programs demonstrating depth and breadth of obesity pipeline Initiated five late-stage global clinical trials in obesity, including the ribupatide injecti...